TGF beta 2 protein (Active) (ab84070)
Our Abpromise guarantee covers the use of ab84070 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Functional Studies||FuncS: Use at an assay dependent dilution.|
|SDS-PAGE||SDS-PAGE: Use at an assay dependent dilution.|
|WB||WB: Use at an assay dependent concentration. Ab84070 can be used as a WB positive control in conjunction with ab66045.|
- BSC-1 cell growth inhibitorBSC1 cell growth inhibitorCetermin
- G-TSFGlioblastoma-derived T-cell suppressor factorGTSFMGC116892MGFMilk growth factorPolyerginTGF-beta-2TGF-beta2TGFB2TGFB2_HUMANTransforming growth factor beta 2Transforming growth factor beta-2
Defects in TGFB2 are the cause of Loeys-Dietz syndrome 4 (LDS4) [MIM:614816]. An aortic aneurysm syndrome with widespread systemic involvement. LDS4 is characterized by arterial tortuosity, aortic dissection, intracranial aneurysm and subarachnoid hemorrhage, hypertelorism, bifid uvula, pectus deformity, bicuspid aortic valve, arachnodactyly, scoliosis, foot deformities, dural ectasia, joint hyperflexibility, and thin skin with easy bruising and striae.
TGF beta 2 protein (Active) images
Anti-TGF beta 2 antibody (ab66045) at 1 µg/ml +
TGF beta 2 protein (Active) (ab84070) at 0.1 µg
Goat polyclonal Secondary Antibody to Rabbit IgG - H&L (HRP), pre-adsorbed (ab97080) at 1/5000 dilution
developed using the ECL technique
Performed under reducing conditions.
Exposure time : 1 minute
References for TGF beta 2 protein (Active) (ab84070)
This product has been referenced in:
- Tran DQ et al. GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3+ regulatory T cells. Proc Natl Acad Sci U S A 106:13445-50 (2009). Read more (PubMed: 19651619) »
- O'Riordan E et al. Chronic NOS inhibition actuates endothelial-mesenchymal transformation. Am J Physiol Heart Circ Physiol 292:H285-94 (2007). Read more (PubMed: 16963618) »